Can analysts adopt a bullish outlook for Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)?

October 13, 2018 - By Vivian Park

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) LogoInvestors sentiment increased to 1.11 in Q2 2018. Its up 0.05, from 1.06 in 2018Q1. It is positive, as 16 investors sold Ligand Pharmaceuticals Incorporated shares while 109 reduced holdings. 42 funds opened positions while 97 raised stakes. 22.99 million shares or 1.94% more from 22.56 million shares in 2018Q1 were reported.
Schwab Charles Investment Inc owns 0.02% invested in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) for 135,871 shares. Victory Cap Mngmt reported 537,355 shares. Teacher Retirement Systems Of Texas invested in 4,281 shares or 0.01% of the stock. Matarin Cap Management holds 0% or 41,201 shares in its portfolio. First Republic Investment Mngmt Inc invested 0.01% in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND). Blair William & Il accumulated 138,058 shares. Intrust Savings Bank Na owns 3,529 shares or 0.2% of their US portfolio. Assetmark has invested 0% in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND). Boston Advisors has invested 0.03% of its portfolio in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND). Alps Advsrs reported 23,386 shares stake. M&T National Bank reported 0% in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND). Zurcher Kantonalbank (Zurich Cantonalbank) holds 0% or 1,326 shares. Los Angeles Equity has invested 0% of its portfolio in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND). Bogle Inv Lp De has 50,824 shares. Winslow Evans Crocker invested in 0.15% or 2,300 shares.

Since May 10, 2018, it had 0 insider buys, and 15 insider sales for $48.89 million activity. The insider Patel Sunil sold $10.15M. Another trade for 5,000 shares valued at $1.28 million was sold by Sabba Stephen L. The insider HIGGINS JOHN L sold 34,500 shares worth $8.35 million. $4.95M worth of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) was sold by Berkman Charles S on Tuesday, September 4. LAMATTINA JOHN L sold $850,292 worth of stock or 3,335 shares. The insider Korenberg Matthew E sold 18,357 shares worth $4.71 million.

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Ratings Coverage

Among 5 analysts covering Ligand Pharmaceuticals (NASDAQ:LGND), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. Ligand Pharmaceuticals had 5 analyst reports since June 21, 2018 according to SRatingsIntel. The firm earned “Buy” rating on Wednesday, September 19 by H.C. Wainwright. Roth Capital downgraded Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) on Wednesday, August 8 to “Neutral” rating. The rating was maintained by Craig Hallum with “Buy” on Wednesday, June 27. Below is a list of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) latest ratings and price target changes.

19/09/2018 Broker: H.C. Wainwright Old Rating: Buy New Rating: Buy Old Target: $257 New Target: $270 Maintain
17/08/2018 Broker: Goldman Sachs Rating: Neutral New Target: $256 Initiates Coverage On
08/08/2018 Broker: Roth Capital Old Rating: Buy New Rating: Neutral Downgrade
27/06/2018 Broker: Craig Hallum Rating: Buy New Target: $230.0000 Maintain
21/06/2018 Broker: Argus Research Rating: Buy New Target: $260 Initiates Coverage On

The stock decreased 1.50% or $3.08 during the last trading session, reaching $202.59. About 1.27M shares traded or 207.85% up from the average. Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) has risen 86.03% since October 13, 2017 and is uptrending. It has outperformed by 70.41% the S&P500.

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. The company has market cap of $4.28 billion. The Company’s commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis and Evomela, which are used to treat multiple myeloma; CorMatrix portfolio of vascular, cardiac, and pericardial tissue repair products; bazedoxifene, which is used for the treatment of postmenopausal osteoporosis; Carnexiv that is used as replacement therapy for oral carbamazepine formulations; Nexterone, a Captisol-enabled formulation of amiodarone; Noxafil-IV, a Captisol-enabled formulation of posaconazole for IV use; Exemptia for autoimmune diseases; and Vivitra for breast cancer. It has a 40.99 P/E ratio. The companyÂ’s partners programs, which are in clinical development used for the treatment of seizure, coma, cancer, diabetes, cardiovascular disease, muscle wasting, liver disease, kidney disease, and others.

More notable recent Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) news were published by: Nasdaq.com which released: “Sermonix Launches Phase 2 Trial to Evaluate Investigational Oral Lasofoxifene as a Targeted Precision Treatment for …” on October 09, 2018, also Investorplace.com with their article: “10 Triple-A Stocks to Buy for the Rest of 2018” published on September 28, 2018, Fool.com published: “3 Top Mid-Cap Stocks to Buy Right Now” on October 06, 2018. More interesting news about Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) were released by: Investorplace.com and their article: “The 10 Best Stocks to Buy Right Now” published on September 24, 2018 as well as Streetinsider.com‘s news article titled: “Ligand Pharma (LGND) PT Raised to $280 at HC Wainwright” with publication date: October 02, 2018.

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

>